These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 22406151)

  • 1. Design and synthesis of orally available MEK inhibitors with potent in vivo antitumor efficacy.
    Adams ME; Wallace MB; Kanouni T; Scorah N; O'Connell SM; Miyake H; Shi L; Halkowycz P; Zhang L; Dong Q
    Bioorg Med Chem Lett; 2012 Apr; 22(7):2411-4. PubMed ID: 22406151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-based design and synthesis of pyrrole derivatives as MEK inhibitors.
    Wallace MB; Adams ME; Kanouni T; Mol CD; Dougan DR; Feher VA; O'Connell SM; Shi L; Halkowycz P; Dong Q
    Bioorg Med Chem Lett; 2010 Jul; 20(14):4156-8. PubMed ID: 20621728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design and synthesis of novel allosteric MEK inhibitor CH4987655 as an orally available anticancer agent.
    Isshiki Y; Kohchi Y; Iikura H; Matsubara Y; Asoh K; Murata T; Kohchi M; Mizuguchi E; Tsujii S; Hattori K; Miura T; Yoshimura Y; Aida S; Miwa M; Saitoh R; Murao N; Okabe H; Belunis C; Janson C; Lukacs C; Schück V; Shimma N
    Bioorg Med Chem Lett; 2011 Mar; 21(6):1795-801. PubMed ID: 21316218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimization of a dihydropyrrolopyrazole series of transforming growth factor-beta type I receptor kinase domain inhibitors: discovery of an orally bioavailable transforming growth factor-beta receptor type I inhibitor as antitumor agent.
    Li HY; McMillen WT; Heap CR; McCann DJ; Yan L; Campbell RM; Mundla SR; King CH; Dierks EA; Anderson BD; Britt KS; Huss KL; Voss MD; Wang Y; Clawson DK; Yingling JM; Sawyer JS
    J Med Chem; 2008 Apr; 51(7):2302-6. PubMed ID: 18314943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design and synthesis of orally bioavailable benzimidazoles as Raf kinase inhibitors.
    Ramurthy S; Subramanian S; Aikawa M; Amiri P; Costales A; Dove J; Fong S; Jansen JM; Levine B; Ma S; McBride CM; Michaelian J; Pick T; Poon DJ; Girish S; Shafer CM; Stuart D; Sung L; Renhowe PA
    J Med Chem; 2008 Nov; 51(22):7049-52. PubMed ID: 18942827
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of pyrroloaminopyrazoles as novel PAK inhibitors.
    Guo C; McAlpine I; Zhang J; Knighton DD; Kephart S; Johnson MC; Li H; Bouzida D; Yang A; Dong L; Marakovits J; Tikhe J; Richardson P; Guo LC; Kania R; Edwards MP; Kraynov E; Christensen J; Piraino J; Lee J; Dagostino E; Del-Carmen C; Deng YL; Smeal T; Murray BW
    J Med Chem; 2012 May; 55(10):4728-39. PubMed ID: 22554206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery and synthesis of novel 4-aminopyrrolopyrimidine Tie-2 kinase inhibitors for the treatment of solid tumors.
    Arcari JT; Beebe JS; Berliner MA; Bernardo V; Boehm M; Borzillo GV; Clark T; Cohen BD; Connell RD; Frost HN; Gordon DA; Hungerford WM; Kakar SM; Kanter A; Keene NF; Knauth EA; Lagreca SD; Lu Y; Martinez-Alsina L; Marx MA; Morris J; Patel NC; Savage D; Soderstrom CI; Thompson C; Tkalcevic G; Tom NJ; Vajdos FF; Valentine JJ; Vincent PW; Wessel MD; Chen JM
    Bioorg Med Chem Lett; 2013 May; 23(10):3059-63. PubMed ID: 23566514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design and evaluation of a series of pyrazolopyrimidines as p70S6K inhibitors.
    Bussenius J; Anand NK; Blazey CM; Bowles OJ; Bannen LC; Chan DS; Chen B; Co EW; Costanzo S; DeFina SC; Dubenko L; Engst S; Franzini M; Huang P; Jammalamadaka V; Khoury RG; Kim MH; Klein RR; Laird D; Le DT; Mac MB; Matthews DJ; Markby D; Miller N; Nuss JM; Parks JJ; Tsang TH; Tsuhako AL; Wang Y; Xu W; Rice KD
    Bioorg Med Chem Lett; 2012 Mar; 22(6):2283-6. PubMed ID: 22342124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis of phenanthroindolizidine alkaloids and evaluation of their antitumor activities and toxicities.
    Ikeda T; Yaegashi T; Matsuzaki T; Yamazaki R; Hashimoto S; Sawada S
    Bioorg Med Chem Lett; 2011 Oct; 21(19):5978-81. PubMed ID: 21865039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis and evaluation of acridine derivatives as multi-target Src and MEK kinase inhibitors for anti-tumor treatment.
    Cui Z; Li X; Li L; Zhang B; Gao C; Chen Y; Tan C; Liu H; Xie W; Yang T; Jiang Y
    Bioorg Med Chem; 2016 Jan; 24(2):261-9. PubMed ID: 26707846
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Highly potent and selective 3-N-methylquinazoline-4(3H)-one based inhibitors of B-Raf(V600E) kinase.
    Wenglowsky S; Ren L; Grina J; Hansen JD; Laird ER; Moreno D; Dinkel V; Gloor SL; Hastings G; Rana S; Rasor K; Sturgis HL; Voegtli WC; Vigers G; Willis B; Mathieu S; Rudolph J
    Bioorg Med Chem Lett; 2014 Apr; 24(8):1923-7. PubMed ID: 24675381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and synthesis of novel DFG-out RAF/vascular endothelial growth factor receptor 2 (VEGFR2) inhibitors: 2. Synthesis and characterization of a novel imide-type prodrug for improving oral absorption.
    Okaniwa M; Imada T; Ohashi T; Miyazaki T; Arita T; Yabuki M; Sumita A; Tsutsumi S; Higashikawa K; Takagi T; Kawamoto T; Inui Y; Yoshida S; Ishikawa T
    Bioorg Med Chem; 2012 Aug; 20(15):4680-92. PubMed ID: 22763369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis, and evaluation of orally active 4-(2,4-difluoro-5-(methoxycarbamoyl)phenylamino)pyrrolo[2,1-f][1,2,4]triazines as dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 inhibitors.
    Borzilleri RM; Zheng X; Qian L; Ellis C; Cai ZW; Wautlet BS; Mortillo S; Jeyaseelan R; Kukral DW; Fura A; Kamath A; Vyas V; Tokarski JS; Barrish JC; Hunt JT; Lombardo LJ; Fargnoli J; Bhide RS
    J Med Chem; 2005 Jun; 48(12):3991-4008. PubMed ID: 15943473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of 4-amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide (AZD5363), an orally bioavailable, potent inhibitor of Akt kinases.
    Addie M; Ballard P; Buttar D; Crafter C; Currie G; Davies BR; Debreczeni J; Dry H; Dudley P; Greenwood R; Johnson PD; Kettle JG; Lane C; Lamont G; Leach A; Luke RW; Morris J; Ogilvie D; Page K; Pass M; Pearson S; Ruston L
    J Med Chem; 2013 Mar; 56(5):2059-73. PubMed ID: 23394218
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis and structure-activity relationships of novel biarylamine-based Met kinase inhibitors.
    Williams DK; Chen XT; Tarby C; Kaltenbach R; Cai ZW; Tokarski JS; An Y; Sack JS; Wautlet B; Gullo-Brown J; Henley BJ; Jeyaseelan R; Kellar K; Manne V; Trainor GL; Lombardo LJ; Fargnoli J; Borzilleri RM
    Bioorg Med Chem Lett; 2010 May; 20(9):2998-3002. PubMed ID: 20382527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimization of 6,6-dimethyl pyrrolo[3,4-c]pyrazoles: Identification of PHA-793887, a potent CDK inhibitor suitable for intravenous dosing.
    Brasca MG; Albanese C; Alzani R; Amici R; Avanzi N; Ballinari D; Bischoff J; Borghi D; Casale E; Croci V; Fiorentini F; Isacchi A; Mercurio C; Nesi M; Orsini P; Pastori W; Pesenti E; Pevarello P; Roussel P; Varasi M; Volpi D; Vulpetti A; Ciomei M
    Bioorg Med Chem; 2010 Mar; 18(5):1844-53. PubMed ID: 20153204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blockade of the extracellular signal-regulated kinase pathway enhances the therapeutic efficacy of microtubule-destabilizing agents in human tumor xenograft models.
    Watanabe K; Tanimura S; Uchiyama A; Sakamoto T; Kawabata T; Ozaki K; Kohno M
    Clin Cancer Res; 2010 Feb; 16(4):1170-8. PubMed ID: 20145173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and biological evaluation of novel pyrrolopyrrolizinones as anticancer agents.
    Rochais C; Lisowski V; Dallemagne P; Rault S
    Bioorg Med Chem; 2006 Dec; 14(24):8162-75. PubMed ID: 17011196
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Naphthamides as novel and potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: design, synthesis, and evaluation.
    Harmange JC; Weiss MM; Germain J; Polverino AJ; Borg G; Bready J; Chen D; Choquette D; Coxon A; DeMelfi T; DiPietro L; Doerr N; Estrada J; Flynn J; Graceffa RF; Harriman SP; Kaufman S; La DS; Long A; Martin MW; Neervannan S; Patel VF; Potashman M; Regal K; Roveto PM; Schrag ML; Starnes C; Tasker A; Teffera Y; Wang L; White RD; Whittington DA; Zanon R
    J Med Chem; 2008 Mar; 51(6):1649-67. PubMed ID: 18324761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Strategies to mitigate the bioactivation of 2-anilino-7-aryl-pyrrolo[2,1-f][1,2,4]triazines: identification of orally bioavailable, efficacious ALK inhibitors.
    Mesaros EF; Thieu TV; Wells GJ; Zificsak CA; Wagner JC; Breslin HJ; Tripathy R; Diebold JL; McHugh RJ; Wohler AT; Quail MR; Wan W; Lu L; Huang Z; Albom MS; Angeles TS; Wells-Knecht KJ; Aimone LD; Cheng M; Ator MA; Ott GR; Dorsey BD
    J Med Chem; 2012 Jan; 55(1):115-25. PubMed ID: 22141319
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.